[1. Hu P, Lu L, Hu B, Du PF. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome. Scand J Clin Lab Invest. 2009; 69:680-6.10.3109/0036551090298075119468931]Open DOISearch in Google Scholar
[2. Marsh JB. Lipoprotein metabolism in experimental nephrosis. Proc Soc Exp Biol Med. 1996; 213:178-86.10.3181/00379727-213-440488931662]Search in Google Scholar
[3. Joven J, Villabona C, Vilella E, Masana L, Albert R, Vall s M. Abnormalities of lipoprotein metabolism in patients with the nephritic syndrome. N Engl J Med. 1990; 323:579-84.10.1056/NEJM1990083032309052381443]Search in Google Scholar
[4. al-Shurbaji A, Humble E, Rudling M, Lindenthal B, Berglund L. Hepatic cholesterol metabolism in experimental nephrotic syndrome. Lipids. 1998; 33: 165-9.10.1007/s11745-998-0192-z9507238]Open DOISearch in Google Scholar
[5. Zhou Y, Zhang X, Chen L, Wu J, Dang H, Wei M, et al. Expression profiling of hepatic genes associated with lipid metabolism in nephrotic rats. Am J Physiol Renal Physiol. 2008; 295:F662-71.10.1152/ajprenal.00046.2008253686818614621]Search in Google Scholar
[6. Liang K, Vaziri ND. Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int. 1997; 51:1933-7.10.1038/ki.1997.2639186885]Open DOISearch in Google Scholar
[7. Vaziri ND, Liang KH. Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int. 1996; 50:887-93.10.1038/ki.1996.3888872963]Open DOISearch in Google Scholar
[8. Lechleitner M. Dyslipidaemia and renal diseasepathophysiology and lipid lowering therapy in patients with impaired renal function. J Clin Basic Cardiol. 2000; 3:3-6.]Search in Google Scholar
[9. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006; 290:F262-72.10.1152/ajprenal.00099.200516403839]Search in Google Scholar
[10. Lechner BL, Bockenhauer D, Iragorri S, Kennedy TL, Siegel NJ. The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr Nephrol. 2004; 19:744-8.10.1007/s00467-004-1460-x15085419]Open DOISearch in Google Scholar
[11. Friedewald WT, Levi RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in serum, without use of the use of preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.10.1093/clinchem/18.6.499]Search in Google Scholar
[12. Grubb A, Nyman U, Bjork J, Lindström V, Rippe B, Sterner G, et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equaions for children. Clin Chem. 2005; 51:1420-31.10.1373/clinchem.2005.05155715961546]Open DOISearch in Google Scholar
[13. Marsik C, Endler G, Gulesserian T, Wagner OF, Sunder- Plassmann G. Classification of chronic kidney disease by estimated glomerular filtration rate. Eur J Clin Invest. 2008; 38:253-9.10.1111/j.1365-2362.2008.01934.x18339005]Open DOISearch in Google Scholar
[14. Hu P, Qin YH, Jing CX, Lei FY, Chen P, Li MF. Association of polymorphisms at restriction enzyme recognition sites of apolipoprotein B and E gene with dyslipidemia in children undergoing primary nephrotic syndrome. Mol Biol Rep. 2009; 36:1015-21.10.1007/s11033-008-9275-718512131]Open DOISearch in Google Scholar
[15. Anochie I, Eke F, Okpere A. Childhood nephrotic syndrome: change in pattern and response to steroids. J Natl Med Assoc. 2006; 98:1977-81.]Search in Google Scholar
[16. Chan CM. Hyperlipidaemia in chronic kidney disease. Ann Acad Med Singapore. 2005; 34:31-5.]Search in Google Scholar
[17. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989; 13:I80-93.10.1161/01.HYP.13.5_Suppl.I802490833]Open DOISearch in Google Scholar
[18. Wheeler DC. Lipids-what is the evidence for their role in progressive renal disease? Nephrol Dial Transplant. 1995; 10:14-6.]Search in Google Scholar
[19. Li J, Yu L, Li N, Wang H. Astragalus mongholicus and Angelica sinensis compound alleviates nephrotic hyperlipidemia in rats. Chin Med J (Engl). 2000; 113: 310-4.]Search in Google Scholar
[20. Hu P, Qin YH, Lu L, Hu B, Jing CX, Lei FY, et al. Genetic variation of apolipoprotein E does not contribute to the lipid abnormalities secondary to childhood minimal change nephrotic syndrome. Int Urol Nephrol. 2010; 42:453-60.10.1007/s11255-009-9531-319241136]Open DOISearch in Google Scholar
[21. De Sain-Van Der Velden MG, Reijngoud DJ, Kaysen GA, Gadellaa MM, Voorbij H, Stellaard F, et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol. 1998; 9: 1474-81.10.1681/ASN.V9814749697670]Search in Google Scholar
[22. Warwick GL, Packard CJ, Demant T, Bedford DK, Boulton-Jones JM, Shepherd J. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int. 1991; 40: 129-38.10.1038/ki.1991.1901921148]Open DOISearch in Google Scholar
[23. Sato T, Liang K, Vaziri ND. Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int. 2003; 64: 1780-6.10.1046/j.1523-1755.2003.00281.x14531811]Search in Google Scholar
[24. Vaziri ND, Kim CH, Phan D, Kim S, Liang K. Upregulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. Kidney Int. 2004; 66:262-7.10.1111/j.1523-1755.2004.00724.x15200432]Open DOISearch in Google Scholar
[25. Vaziri ND, Liang K, Parks JS. Acquired lecithincholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Renal Physiol. 2001; 280: F823-8.10.1152/ajprenal.2001.280.5.F82311292624]Search in Google Scholar
[26. Liang K, Vaziri ND. Down-regulation of hepatic highdensity lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int. 1999; 56:621-6.10.1046/j.1523-1755.1999.00585.x10432401]Open DOISearch in Google Scholar
[27. Majumdar A, Wheeler DC. Lipid abnormalities in renal disease. J R Soc Med. 2000; 93:178-82.10.1177/014107680009300406129797310844882]Search in Google Scholar
[28. Lacquaniti A, Bolignano D, Donato V, Bono C, Fazio MR, Buemi M. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res. 2010; 33:100-10.10.1159/00030271220357496]Open DOISearch in Google Scholar
[29. Liu BC, Wu XC, Wang YL, Wang B, Gao J, Zhang QJ, et al. Investigation of the prevalence of CKD in 13, 383 Chinese hospitalised adult patients. Clin Chim Acta. 2008; 387:128-32.10.1016/j.cca.2007.09.02018028892]Search in Google Scholar
[30. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009; 4:1832-43.10.2215/CJN.0164030919820136]Open DOISearch in Google Scholar
[31. Vaziri ND, Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int. 2006; 10:1-7.10.1111/j.1542-4758.2006.01168.x16441821]Open DOISearch in Google Scholar
[32. Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 2003; 63:1964-76.10.1046/j.1523-1755.2003.00941.x12675893]Open DOISearch in Google Scholar
[33. Yang X, Wang H, Zhu Z, Deng A. Serum lipoprotein (a) concentration in patients with nephrotic syndrome and its clinical implication. J Tongji Med Univ. 1998; 18:236-8.10.1007/BF0288648110806854]Open DOISearch in Google Scholar
[34. Thiery J, Ivandic B, Bahlmann G, Walli AK, Seidel D. Hyperlipoprotein(a)aemia in nephrotic syndrome. Eur J Clin Invest. 1996; 26:316-21.10.1046/j.1365-2362.1996.132283.x8732490]Open DOISearch in Google Scholar
[35. Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther. 2007; 29:763-77.10.1016/j.clinthera.2007.05.00217697898]Open DOISearch in Google Scholar
[36. Araujo Junior MD. Hypertriglyceridemia represents an independent risk for coronary atherosclerosis. Arq Bras Cardiol. 1992; 59:168.]Search in Google Scholar
[37. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007; 176: 1113-20.10.1503/cmaj.060963]Search in Google Scholar
[38. Kim SB, Kang SA, Cho YJ, Park SK, Cheong HI, Lee JD, et al. Effects of low density lipoprotein on type IV collagen production by cultured rat mesangial cells. Nephron. 1994; 67:327-33.10.1159/000187988]Open DOISearch in Google Scholar
[39. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, et al. Urinary excretion of fatty acidbinding protein reflects stress overload on the proximal tubules. Am J Pathol. 2004; 165:1243-55.10.1016/S0002-9440(10)63384-6]Search in Google Scholar
[40. Moradi H, Yuan J, Ni Z, Norris K, Norris K, Vaziri ND. Reverse cholesterol transport pathway in experimental chronic renal failure. Am J Nephrol. 2009; 30:147-54. 10.1159/000210020281381019321994]Open DOISearch in Google Scholar